DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

Information source: University of Michigan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Idiopathic Pulmonary Fibrosis

Intervention: zileuton (Drug); azathioprine/prednisone (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Michigan

Official(s) and/or principal investigator(s):
Galen B Toews, MD, Principal Investigator, Affiliation: University of Michigan

Summary

Open label trial of zileuton compared to azathioprine/prednisone for patients with idiopathic pulmonary fibrosis. Study subjects will undergo a detailed clinical, radiographic, and physiologic assessment at baseline. Subjects will be monitored off treatment for three months for changes in symptoms and physiology. Subjects will then be randomized to six months of treatment with zileuton or azathioprine/prednisone. The primary endpoint of this trial is change in LTB4 levels in bronchoalveolar lavage fluid following six months of treatment. Secondary endpoints are progression free survival, change in dyspnea, change in quality of life, and change in physiology.

Clinical Details

Official title: Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: LTB4 level in BAL

Secondary outcome: CRP score

Eligibility

Minimum age: 35 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of idiopathic pulmonary fibrosis

- Taking < 15 mg prednisone for at least 30 days prior to screening

- Age 35-80, inclusive

- Able to understand a written informed consent and comply with the study protocol

Exclusion Criteria:

- Significant environmental exposure

- Diagnosis of collagen vascular disease

- Evidence of active infection

- Clinically significant cardiac disease Myocardial infarction, coronary artery bypass

or angioplasty within 6mo Unstable angina pectoris Congestive heart failure requiring hospitalization within 6 months Uncontrolled arrhythmia

- Poorly controlled or severe diabetes mellitus

- Pregnancy or lactation

- Women of childbearing potential not using a medically approved means of contraception

(i. e. oral contraceptives, intrauterine devices, diaphragm, Norplant)

- Current enrollment in another experimental protocol

Physiologic Criteria:

- FEV1/FVC < 0. 60

Laboratory Criteria:

- Total bilirubin > 1. 5 X upper limit normal

- AST or ALT > 3X upper limit normal

- Alkaline phosphatase > 3X upper limit normal

- White blood cell count < 2,500/mm3

- Hematocrit < 30%

- Platelets < 100,000/mm3

- Prothrombin time INR > 1. 5

Locations and Contacts

University of Michigan, Ann Arbor, Michigan 48109, United States
Additional Information

Starting date: January 2001
Last updated: March 5, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017